



Citation for published version:

Yang, Z, Kasprzyk-Hordern, B, Frost, C, Estrela, P & Thomas, KV 2015, 'Community Sewage Sensors for Monitoring Public Health', *Environmental Science & Technology*, vol. 49, no. 10, pp. 5845-5846.
<https://doi.org/10.1021/acs.est.5b01434>

DOI:

[10.1021/acs.est.5b01434](https://doi.org/10.1021/acs.est.5b01434)

Publication date:

2015

Document Version

Early version, also known as pre-print

[Link to publication](#)

University of Bath

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

2 **Community Sewage Sensors for Monitoring Public Health**

3 Zhugen Yang^{1,2*}, Barbara Kasprzyk-Hordern¹, Christopher G. Frost^{1*}, Pedro Estrela², Kevin
4 V. Thomas³

5 ¹*Department of Chemistry, University of Bath, Claverton Down, BA2 7AY, Bath, UK*

6 ²*Department of Electronic and Electrical Engineering, University of Bath, Claverton Down,
7 BA2 7AY, Bath, UK*

8 ³*Norwegian Institute for Water Research (NIVA), Gaustadalléen 21, 0349 Oslo, Norway*

9 Corresponding authors: Dr Z. Yang (zhugen.yang@gmail.com) Tel.: +44 (0)1225 386 071;
10 fax: +44 (0)1225 386 231 and Prof C.G. Frost (c.g.frost@bath.ac.uk) Tel.: +44 (0)1225 386
11 142; fax: +44 (0)1225 386 231

12 Wastewater-based epidemiology (WBE) has been shown to be an innovative approach
13 for monitoring drug use in communities by quantifying drug residues (so-called “drug
14 biomarkers”) in sewage^{1, 2}. WBE has thus far been validated by assessing illicit drug use
15 trends across Europe, with the evaluation of spatial differences and temporal changes in the
16 levels of specific biomarkers in sewage from 42 cities in 21 European countries (total
17 population 24.74 million)¹. It is hypothesized that sewage contains additional information on
18 the lifestyle, health and pollutant exposure of a community which could also be obtained by
19 the analysis of sewage biomarkers². In fact, feces and urine from either humans or animals
20 carry many biomarkers and pathogens, which could and enter the sewer system from a carrier
21 of the disease in the community, e.g. patients at hospitals. Those pathogens such as bacteria,
22 viruses and parasites in wastewater are hazardous to humans because they might cause
23 epidemics in population. However, human hazards can be minimized if those pathogens
24 could be monitored at an early stage in the community. Unlike illicit drug use trends,
25 infectious diseases require rapid or even real-time detection to assess whether there is a need
26 for the containment of the disease carriers to certain areas and prevent the development of an
27 epidemic. To this end, there is a need to develop novel analytical tools that are able to
28 accurately and rapidly monitor low levels of biomarkers/pathogens with minimal sample
29 processing by unskilled personnel at the site of sample collection. **Emerging biosensing
30 technology will play a key role in the in situ quantitative analysis of biomarkers and
31 pathogens in sewage due to rapid response times, low cost, minimal sample processing, high
32 data resolution and ability to operate remotely. Community sewage sensors employed to
33 detect biomarkers of health and diseases at a population-level have therefore the clear
34 potential to provide real-time data for the assessment of community-wide health.**

35 Biosensors have emerged as powerful tools for the detection of disease biomarkers for
36 both healthcare and environmental monitoring. A biosensor is a small device with a
37 biological receptor (DNA, antibody, protein etc.) that generates a signal (electrochemical,
38 optical, piezoelectric, nanomechanical, mass sensitive etc.) in the presence of an analytical
39 target (analyte). Compared to conventional analytical tools, biosensors can provide rapid
40 response times, ultra-sensitive detection of biomolecules, and the potential to be miniaturized

41 for portable assays requiring minimal sample processing. Moreover, this approach could be
42 employed, not only for the detection of pathogens, but also for the monitoring of more
43 general public health indicators such as obesity, diabetes, high blood pressure and sexually
44 transmitted infections. For example, a recent report demonstrates that the level of an
45 American city's obesity could be predicted by analyzing the bacterial community structure
46 found in sewage³. Such an approach providing near real-time and continuous data would
47 serve as an early warning sensing system to help agencies, such as the "Centre for Disease
48 Control and Prevention" (CDC) in the United States, to make effective interventions to
49 prevent the spread of epidemics, evaluate the effects of interventions and in turn increase the
50 effectiveness of their policies and use of valuable resources. For example, in 2003 the
51 effective interventions of CDC in the United States helped reduced spread of severe acute
52 respiratory syndrome (SARS) to a minimum level.

53 A large number of biosensors have been developed for the detection of disease
54 biomarkers and pathogens in samples such as urine, sera and saliva (Table 1). Although
55 sewage is a complex matrix, spurious effects, such as nonspecific interactions can be
56 minimized provided that an ultra-high affinity probe such as an aptamer is used to target
57 specific analytes, as well as by calculating the differential response of a probe and a reference
58 chip. As an example, a macrocantilever-based label-free biosensor can quantitatively detect a
59 prostate cancer biomarker (α -methylacyl-CoA racemase; AMACR) directly in patients' urine
60 without any sample preparation⁴. Hence, there is the clear potential to develop a wider range
61 of innovative community sensors to quantitatively assess sewage profiles and patterns of
62 factors related to health and illness within populations using WBE. Additionally, biosensors
63 have the potential to be miniaturized to a handheld device for point-of-care analysis that may
64 facilitate the monitoring of infectious diseases in developing countries where the occurring
65 rate (such as malaria, acquired immune deficiency syndrome (AIDS) and tuberculosis) is
66 extremely high. For instance, a plasmonic enzyme-linked immunosorbent assay (ELISA) has
67 been developed to ultra-sensitively detect an HIV-1 capsid antigen p24 at concentrations as
68 low as 1 attogram per millilitre in serum of HIV-infected patients with the naked eye⁵. In this
69 sensor, the ELISA enzyme controls the aggregation of nanoparticles, rising a blue colour if a
70 target protein is present otherwise a red colour if no target. All of these biosensors can
71 potentially be used in sewage matrices as community sensors to assess urinary and fecal
72 biomarkers/pathogens for the monitoring of public health using WBE, while also providing a
73 means of collecting data for epidemiological and socio-economic studies. Community
74 sewage sensors arrays can be customized designed for the monitoring of different
75 biomarkers/pathogens in a single assay. Their use could be of considerable economic and
76 societal impact especially in resource-constrained areas. More importantly, biosensing
77 technology platforms can be utilized to collect information on community-wide health in
78 order to report to health agencies as an early prevention measurement and effective
79 interventions. Although the selectivity and long-term stability of community sensors as well
80 as environmental susceptibility to deterioration of bio-recognition are yet to be addressed, we
81 envisage that the rapid and real-time monitoring of health in communities will soon be
82 possible.

83 Table 1 Examples of biosensors used for the detection of infectious diseases and pathogens

Infectious diseases	Biosensors and its transducers	Biomarkers/pathogens
HIV	Plasmonic ELISA	protein biomarkers
	Impedimetric, voltammetric and amperometric proteins biosensors	HIV virus lysate, HIV-1 protease
	Mechanical sensors	HIV CD4 T cell number
Tuberculosis	Electrochemical PCR-free mycobacterium tuberculosis (MTB) genomic sensors	PCR-free MTB nucleic acid or cells
Others diseases	Fluorescent peptides sensors	Drug resistant chronic myelogenous leukemia
Pathogens	Fluorescent array, evanescent wave fibre-optic, laser cytometry, electrochemical and mass sensitive DNA/antibodies sensors	Pathogenic Bacillus species like Bacillus anthracis and bacillus cereus
	Optical, electrochemical and mass sensitive DNA/ aptamers/antibodies biosensors	campylobacter species for campylobacteriosis
	Fluorescent, electrochemical and piezoelectric antibody/lectin/ganglioside biosensors	cholera toxin from bacterium Vibrio cholera
	Optical, electrochemical, mass sensitive antibodies/antimicrobial peptides/aptamers/bacteriophages biosensors	Escherichia coli, like E coli O157:H7; Listeria monocytogenes,; Salmonella; Shigella spp, Staphylococcus aureus; viral threats (smallpox viral hemorrhagic fevers, viral encephalitis etc.)

84

85 Funding to support SEWPROF MC ITN entitled 'A new paradigm in drug use and
86 human health risk assessment: Sewage profiling at the community level' from the European
87 Union's Seventh Framework Programme for research, technological development and
88 demonstration under grant agreement [317205] is greatly acknowledged. P.E. and C.G.F.
89 acknowledge support from the European Commission FP7 Programme through the Marie
90 Curie Initial Training Network PROSENSE (grant no. 317420, 2012-2016). K.V.T.
91 acknowledges the support of NIVAs Strategic Institute Initiative on Contaminants of
92 Emerging Concern.

93

94 **References**

- 95 1. Ort, C.; van Nuijs, A. L. N.; Berset, J.-D.; Bijlsma, L.; Castiglioni, S.; Covaci, A.; de Voogt,
96 P.; Emke, E.; Fatta-Kassinos, D.; Griffiths, P.; Hernandez, F.; Gonzalez-Marino, I.; Grabic, R.;
97 Kasprzyk-Hordern, B.; Mastroianni, N.; Meierjohann, A.; Nefau, T.; Oestman, M.; Pico, Y.;
98 Racamonde, I.; Reid, M.; Slobodnik, J.; Terzic, S.; Thomaidis, N.; Thomas, K. V., Spatial differences
99 and temporal changes in illicit drug use in Europe quantified by wastewater analysis. *Addiction* **2014**,
100 *109*, (8), 1338-1352.
- 101 2. Thomas, K. V.; Reid, M. J., What Else Can the Analysis of Sewage for Urinary Biomarkers
102 Reveal About Communities? *Environ Sci Technol* **2011**, *45*, (18), 7611-7612.

- 103 3. Newton, R. J.; McLellan, S. L.; Dila, D. K.; Vineis, J. H.; Morrison, H. G.; Eren, A. M.;
104 Sogin, M. L., Sewage reflects the microbiomes of human populations. *MBio* **2015**, *6*, (2), 1-9.
- 105 4. Maraldo, D.; Garcia, F. U.; Mutharasan, R., Method for quantification of a prostate cancer
106 biomarker in urine without sample preparation. *Anal Chem* **2007**, *79*, (20), 7683-7690.
- 107 5. de la Rica, R.; Stevens, M. M., Plasmonic ELISA for the ultrasensitive detection of disease
108 biomarkers with the naked eye. *Nat Nanotechnol* **2012**, *7*, (12), 821-824.